[ad_1]
Vaccine maker Pfizer can only deliver half of the vaccines they expected to deliver before the New Year. The company is struggling with the supply of raw materials.
Pharmaceutical manufacturer Pfizer is having trouble sourcing enough raw materials to deliver coronary vaccines as planned.
Zeljko Lukunic / PIXSELL / Pixsell
Published:
The Wall Street Journal writes that Pfizer can only deliver 50 million vaccines before the New Year, while the original plan was to deliver 100 million. However, the company believes that delivery issues will have no consequences for the plan to deliver 1 billion vaccines in 2021.
– The expansion of the raw material supply line took longer than expected. And it is important to emphasize that the outcome of the clinical trials was slightly delayed compared to initial estimates, a company spokesperson told the newspaper.
At the same time, Pfizer found that some of the raw materials they had access to at an early stage were not of sufficient quality.
“We have fixed it, but we could not do it in time to reach the delivery estimates for this year,” a person who has worked on the development of the vaccine told the Wall Street Journal.
The news came just before the close of the Wall Street Stock Exchange. Pfizer shares fell 1.74 percent.
also read
Pfizer vaccine approved in the UK: vaccination to start next week
Different vaccine
Pfizer sources its raw materials from suppliers in Europe and the United States.
The problems that Pfizer has ended up with illustrate how different coronary vaccine development is. Typically, a vaccine manufacturer waits to purchase raw materials for production until after the vaccine has been approved.
Pfizer has never before produced a vaccine that uses so-called mRNA technology.
– For this vaccine, everything has happened at the same time. We started setting up supply chains in March, when the vaccine was still in development. It’s never happened before, says the Pfizer employee the Wall Street Journal spoke to.
also read
Bet more than 30 billion on the collapse of the candidate vaccine
also read
Seeking approval of a new vaccine candidate in Europe
It can cause problems for the British
The delivery problems could have consequences for the UK, which approved the Pfizer vaccine and ordered 40 million doses.
Norway also hopes to be able to start mass vaccination with the Pfizer vaccine, but depends on the EU approving it first. This is expected to happen at a meeting on December 29.
The Pfizer vaccine provides protection against COVID-19 in 95 percent of cases, based on preliminary test results. No serious side effects have been reported. The vaccine is taken in two doses, three weeks apart. It will reportedly cost around 180 crowns per dose.
also read
The fever of vaccines in the pharmaceutical industry: so much is what the Petroleum Fund owns
Wall Street Journal: Pfizer Slashes Its Original Vaccine Target After Logistical Problems
